Company News in the Life Science Industry

Reset 

KALY - Kali-Extracts Confirms Scheduled Update on Capital Infusion Plan at $50 Million Valuation

DALLAS, Dec. 9, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today confirmed plans to publish an update tomorrow on Tuesday, December 10, 2019 to present capital infusion plans for the company's cannabis extract biopharmaceutical business... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019
Related companies:  Kalytera Therapeutics, Inc.

Stadius Biopharma to Present Data on Fully Human Antibodies for the Treatment of Candida Infections

NEW ORLEANS, Dec. 9, 2019 /PRNewswire/ -- Stadius Biopharma LLC will present data on its fully human antibodies to Candida at the upcoming Antibody Engineering & Therapeutics meeting December 9 - 13, 2019 in San Diego. The antibodies protect mice from death in lethal mouse models... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019

Global Hematology Testing Market Analysis and Forecast, 2019-2029

DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019

New Menarini CELLSEARCH Studies to be Presented at San Antonio Breast Cancer Symposium

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 9, 2019 /PRNewswire/ -- Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, announced today that new research utilizing the company's CELLSEARCH(®) Circulating Tumor Cell (CTC) test will be featured at the upcoming... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019

GVB Biopharma Begins Research on CBT (Cannabicitran), Unexplored Cannabinoid

LAS VEGAS, Dec. 9, 2019 /PRNewswire/ -- GVB Biopharma, a leading hemp cannabinoid producer, announced today that its research and... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019

Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma

NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, is pleased to announce... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019
Related companies:  Hoth Therapeutics

Medline Awards Five Community Health Centers Grants to Improve Patient Care

NORTHFIELD, Ill., Dec. 9, 2019 /PRNewswire/ -- Medline and the Medline Foundation have awarded five community health centers grants to improve patient care and increase access to quality healthcare. The recipients are federally-qualified health centers that serve a large number of underserved... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019
Related companies:  MEDLINE INDUSTRIES. INC.

OSF Ventures Backs Company Behind Medical Device that's Improving Pediatric Care

PEORIA, Ill., Dec. 9, 2019 /PRNewswire/ -- A pilot program using the LifeFlow® device to rapidly infuse septic pediatric patients with fluids is showing promising results and OSF HealthCare will likely expand use to include children who are experiencing low blood pressure because of trauma,... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019
Related companies:  OSF Healthcare System

Canopy Growth Announces David Klein as New Chief Executive Officer

Mark Zekulin to Step Down Within Current Year as Planned

Read more ››
By: PR Newswire Association LLC. - 09 Dec 2019

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

VANCOUVER, Dec. 9, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019
Related companies:  InMed Pharmaceuticals Inc.

Folium Labs Inc Announces Closing of a New Investment Round and Receives NRC-IRAP Grant from the Government of Canada to Support IP Strategy

TORONTO, Dec. 9, 2019 /CNW Telbec/ - Canadian biotechnology company, Folium Labs Inc., gains an undisclosed investment led by YEDI Venture Fund to support the development of a new line of LIVLI products and respective IP. This is the second round led by YEDI following the successful launch and... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019

BIOREM Announces New Orders totalling $5.7 Million and Continued China Expansion

GUELPH, ON, Dec. 9, 2019 /CNW/ - BIOREM Inc. (TSXV: BRM) ("BIOREM" or "the Company") today announced new orders totalling $5.7 million. The orders are for air emission abatement projects in China and North America.

Read more ››
By: PR Newswire Association LLC. - 09 Dec 2019
Related companies:  Biorem Technologies Inc.

CMR Surgical announces appointment of new Chief Executive Officer

Read more ››
By: GlobenewsWire - 09 Dec 2019
Related companies:  CMR Surgical Ltd.

AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood

Read more ››
By: GlobenewsWire - 09 Dec 2019
Related companies:  AllianceBernstein L.P.

Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND

Read more ››
By: GlobenewsWire - 09 Dec 2019
Related companies:  Orion Corporation | Orion Corporation

Orion Corporation: Managers’ transactions – Agendum Oy

Read more ››
By: GlobenewsWire - 09 Dec 2019
Related companies:  Orion Corporation | Orion Corporation

Orion Corporation: Managers’ transactions – Mikael Silvennoinen

Read more ››
By: GlobenewsWire - 09 Dec 2019
Related companies:  Orion Corporation | Orion Corporation

Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough

Read more ››
By: GlobenewsWire - 09 Dec 2019

17th Guignolée Dr Julien fundraiser on Saturday, December 14, 2019

Read more ››
By: GlobenewsWire - 09 Dec 2019

BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

BERGEN, Norway, Dec. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will today provide an update from the Company's phase II study of bemcentinib (BGB324), a first-in-class... Read more ››

By: PR Newswire Association LLC. - 09 Dec 2019
Related companies:  BerGenBio ASA
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25

Explore our database of over 50,000 companies